Paperonium

← Back to the plain-language case

Abstract reports 11 of 34 combination-arm responders; Results and Table 2 support 8 confirmed, 9 overall

Clin Cancer Res (2021) · doi:10.1158/1078-0432.CCR-21-2160 · PMC9401547

Summary

The abstract's only efficacy result for this first-in-human trial of MK-4830 is that "Eleven of 34 patients in the dose-escalation phase who received combination therapy achieved objective responses", which implies a response rate of 32.4%. The Results and Table 2 place those 11 responders across all 84 treated patients: 1 on monotherapy, 8 confirmed plus 1 unconfirmed among the 34 patients in the combination arm (part C), and 1 among the 18 patients who crossed over from monotherapy. The combination arm therefore has 8 of 34 confirmed responders (23.5%, the 24% ORR in Table 2), or 9 of 34 (26.5%) counting the unconfirmed one, and no grouping in the paper gives 11 responders among combination-treated patients. ORR was a tertiary endpoint and the safety conclusions are unaffected, but the abstract overstates the arm's response count by 3 patients and its response rate by 8.8 percentage points.

What the paper reports

All quotations were checked verbatim against the PMC-archived text.

Abstract, Results:

Of 84 patients, 50 received monotherapy and 34 received combination therapy.

Eleven of 34 patients in the dose-escalation phase who received combination therapy achieved objective responses; 5 previously had progressive disease on anti–PD-1/PD-L1 therapies.

Results, "Tumor response" (one paragraph, quoted in order):

Eleven of 84 patients (10 confirmed and 1 unconfirmed) with heavily pretreated advanced solid tumors in the dose-escalation phase of the trial achieved an objective response. One of 50 patients in the monotherapy group achieved a confirmed partial response (PR) for an ORR of 2% (Table 2)

Eight of 34 patients receiving combination therapy achieved a confirmed response (CR, n = 1; PR, n = 7) and 6 additional patients had SD ≥6 months (per RECIST v1.1 by investigator review) for an ORR of 24% and a DCR of 41% (Table 2; Supplementary Table S2). One additional patient in the combination treatment group achieved an unconfirmed PR. In the crossover group, 1 patient with MSI-high colorectal cancer achieved a confirmed PR.

In addition, 5 of 11 patients (45%) who achieved a response (4 confirmed and 1 unconfirmed) had previous disease progression on an anti–PD-1/PD-L1 alone or in combination with other agents.

Reductions in target lesion size of ≥30% were observed in the patient receiving monotherapy and the 10 patients receiving combination therapy (including those who crossed over; Fig. 2C and D).

Results, "Safety":

Of the 52 patients treated with combination therapy (n = 34 in part C; n = 18 who crossed over from parts A and B), 48 (92%) experienced AEs (Table 1)

Results, "Biomarker analysis > PD-L1":

Of the 34 patients in the dose-escalation phase who received combination therapy, 25 [6 responders (CR or PR), 19 nonresponders (SD, PD, or missing, including 5 patients with SD and PFS of ≥6 months)] had evaluable PD-L1 status (Fig. 3A).

Table 2, "Summary of confirmed tumor response per RECIST v1.1 by investigator assessment" (excerpt; columns are MK-4830 monotherapy, MK-4830 + pembrolizumab, crossover to MK-4830 + pembrolizumab):

Confirmed response, n (%) | n = 50 | n = 34 | n = 18
ORR | 1 (2)a | 8 (24)b | 1 (6)c
CR | 0 | 1 (3) | 0
PR | 1 (2) | 7 (21) | 1 (6)

Discussion, second paragraph:

45% of patients achieved a PR with MK-4830 plus pembrolizumab after previous disease progression on an anti–PD-1/PD-L1 alone or in combination with other agents

What the paper's own numbers show

Method. I tallied responders by treatment group from the Results text and Table 2. I then tried every numerator and denominator the paper defines for combination therapy: part C confirmed, part C including the unconfirmed PR, and all 52 patients who ever received the combination (part C plus crossover). I also checked Table 2's row sums and percentages, and computed exact (Clopper–Pearson) 95% CIs to show how large the discrepancy is. Every number below is printed by recompute.py.txt.

Quantity Location Reported Recomputed from the paper's own numbers
Responders, all 84 dose-escalation patients Results, Tumor response 11 of 84 (10 confirmed, 1 unconfirmed) 1 mono + 8 part C confirmed + 1 part C unconfirmed + 1 crossover = 11 of 84 (13.1%); 10 confirmed, 1 unconfirmed. Consistent
Responders, 34 combination (part C) patients Abstract, Results 11 of 34 (implies 32.4%) 8 of 34 confirmed (23.5%); 9 of 34 with the unconfirmed PR (26.5%)
Responders on any combination therapy Safety gives 52 combination-treated; Tumor response gives "the 10 patients receiving combination therapy (including those who crossed over)" — 8 + 1 + 1 = 10 of 52 (19.2%); 11 is not reachable
Combination ORR Table 2; Results 8 (24%) 8/34 = 23.5%. Consistent
Combination responders by tumor type Table 2, footnote b 2 + 2 + 1 + 1 + 1 + 1 8. Consistent with Table 2
Combination DCR Results 41% (8 + 6)/34 = 41.2%. Consistent
Combination row of Table 2 Table 2 CR 1, PR 7, SD 9, PD 16, no assessment 1 sums to 34. Consistent
Excess in the abstract — — 11 − 8 = 3 patients; 32.4 − 23.5 = 8.8 percentage points (37.5% relative); 5.9 points above 9/34
Exact 95% CI — not reported 11/34: 17.4–50.5%; 8/34: 10.7–41.2%; 9/34: 12.9–44.4%; 10/52: 9.6–32.5%
Responders with prior anti-PD-1/PD-L1 progression Abstract; Results "5" (abstract, of combination responders); "5 of 11 (45%)" (Results, of all responders) 5/11 = 45.5%

The Results paragraph is self-consistent: its group counts add to exactly the 11 of 84 it states, and the separate statement that 10 combination-treated patients (counting crossovers) had at least 30% tumor shrinkage matches the 8 + 1 + 1 combination-treated responders. Table 2 and its footnote both give 8 confirmed combination responders. The abstract keeps the numerator of the whole-trial statement (11) and swaps the denominator for the part C count (34). The combination arm's own count is 8 confirmed, or 9 with the unconfirmed PR, so 11 of 34 overstates it.

Figure

The abstract's 11 of 34 is the whole-trial responder total placed over the combination-arm denominator

Figure 1. Left: the abstract's statement and the response rate it implies (orange, 11/34 = 32.4%). Right: the Results statement for all 84 patients and the per-group counts given in the Results text and Table 2. They add to 11 responders across monotherapy, part C combination and crossover. The part C combination arm has 8 confirmed responders (23.5%), or 9 (26.5%) counting one unconfirmed PR (blue, recomputed). The connector marks the conflict: the abstract's numerator is the total for all 84 patients, and its denominator is the 34 patients in part C.

The abstract's implied response rate sits above every combination-arm rate the paper's counts support

Figure 2. Objective response rate with exact (Clopper–Pearson) 95% confidence intervals on one linear axis starting at 0. Orange: the rate implied by the abstract (11/34). Blue: the rates the paper's own counts give for the combination arm (8/34 confirmed as in Table 2; 9/34 including the unconfirmed PR) and for every patient who received combination therapy, including crossovers (10/52). The intervals overlap because the arm is small. The figure shows the size of the overstatement. It is not a test.

Why it matters

Explanations considered

Status

Suggested correction

In the abstract, replace

Eleven of 34 patients in the dose-escalation phase who received combination therapy achieved objective responses; 5 previously had progressive disease on anti–PD-1/PD-L1 therapies.

with wording that matches the Results and Table 2, for example

Eight of 34 patients who received combination therapy in the dose-escalation phase achieved a confirmed objective response (ORR 24%) and 1 had an unconfirmed response; overall, 11 of 84 patients responded, of whom 5 previously had progressive disease on anti–PD-1/PD-L1 therapies.

If the 5 patients with prior anti-PD-1/PD-L1 progression were all in the combination arm, the authors may prefer to say so explicitly. In the Discussion, "45% of patients achieved a PR with MK-4830 plus pembrolizumab after previous disease progression" could read "5 of 11 responders (45%) had previous disease progression on an anti–PD-1/PD-L1". The authors may also wish to correct the monotherapy "SD with PFS ≥6 months" cell in Table 2 to "5 (10)" and check the denominator behind "51% of patients with responses".